Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
07 mai 2024 12h30 HE
|
Annexon Biosciences
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision:...
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
01 mai 2024 08h00 HE
|
Annexon Biosciences
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16 avr. 2024 16h05 HE
|
Annexon Biosciences
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 08h00 HE
|
Annexon Biosciences
BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with...
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
26 mars 2024 16h05 HE
|
Annexon Biosciences
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024,...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
18 mars 2024 16h05 HE
|
Annexon Biosciences
BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
27 févr. 2024 08h00 HE
|
Annexon Biosciences
BRISBANE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
21 févr. 2024 08h00 HE
|
Annexon Biosciences
Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
20 févr. 2024 16h05 HE
|
Annexon Biosciences
BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
07 janv. 2024 20h00 HE
|
Annexon Biosciences
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in...